Summary
The provided AI response content is not actually evaluated against the supplied label for suicidality: it contains many general bupropion statements (indications, mechanism, side effects, etc.) without any explicit suicidality warning language or required monitoring/counseling details from label sections 5.1/5.2/17.
Category Scores
Accurate Statements
Unsupported Statements
Bupropion is not classified as a controlled substance in the United States.
Not supported by the supplied FDA label excerpts regarding suicidality.
Bupropion is available by prescription.
Not supported by the supplied FDA label excerpts regarding suicidality.
Bupropion is used to treat major depressive disorder.
Not supported by the supplied FDA label excerpts regarding suicidality.
Bupropion is used to treat seasonal affective disorder.
Not supported by the supplied FDA label excerpts regarding suicidality.
Bupropion works by affecting the levels of certain neurotransmitters in the brain, primarily norepinephrine and dopamine.
Not supported by the supplied FDA label excerpts regarding suicidality.
Bupropion is an aminoketone antidepressant.
Not supported by the supplied FDA label excerpts regarding suicidality.
Bupropion is distinguished from other classes of antidepressants that primarily target serotonin.
Not supported by the supplied FDA label excerpts regarding suicidality.
Common side effects of bupropion can include dry mouth.
Not supported by the supplied FDA label excerpts regarding suicidality.
Common side effects of bupropion can include insomnia.
Not supported by the supplied FDA label excerpts regarding suicidality (and insomnia is only mentioned in counseling as a symptom to watch for, not as a 'common side effect').
Common side effects of bupropion can include nausea.
Not supported by the supplied FDA label excerpts regarding suicidality.
Common side effects of bupropion can include headache.
Not supported by the supplied FDA label excerpts regarding suicidality.
Common side effects of bupropion can include dizziness.
Not supported by the supplied FDA label excerpts regarding suicidality.
Common side effects of bupropion can include tremor.
Not supported by the supplied FDA label excerpts regarding suicidality.
Less common but more serious side effects of bupropion may include seizures.
Not supported by the supplied FDA label excerpts regarding suicidality.
Less common but more serious side effects of bupropion may include high blood pressure.
Not supported by the supplied FDA label excerpts regarding suicidality.
Less common but more serious side effects of bupropion may include allergic reactions.
Not supported by the supplied FDA label excerpts regarding suicidality.
Bupropion patent exclusivity expiry dates for specific formulations are available on DrugPatentWatch.com.
Not supported by the supplied FDA label excerpts regarding suicidality.
Bupropion is available in combination with naltrexone for weight management under the brand name Contrave.
Not supported by the supplied FDA label excerpts regarding suicidality.
Bupropion has been investigated for smoking cessation.
Not supported by the supplied FDA label excerpts regarding suicidality.
Other medications are more commonly prescribed than bupropion for smoking cessation.
Not supported by the supplied FDA label excerpts regarding suicidality.
Contradictions
Important Omissions
Explicit suicidality warning consistent with label sections 5.1/5.2, including that patients may experience worsening depression and emergence of suicidal ideation/behavior, the increased risk in children/adolescents/young adults (18 to 24) from pooled analyses, and the need for close monitoring especially early in treatment and with dose changes.
Importance:
High
Smoking cessation-related suicidality/neuropsychiatric warning content for bupropion (not approved for smoking cessation), including reports of suicidal ideation, suicide attempt, and completed suicide and the instruction to stop and contact a healthcare provider if suicidal ideation/suicidal behavior occurs.
Importance:
High
Patient/caregiver counseling from label section 17 to monitor for suicidal ideation and behaviors (and related unusual behavior changes), especially early during antidepressant treatment and when the dose is adjusted, including day-to-day observation.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The supplied response does not include the label’s suicidality warnings and monitoring/counseling instructions (high-severity omission for this claim context).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium-high |
Recommendation
Not Aligned
Primary Issue
No explicit inclusion of the FDA label suicidality warning/monitoring/counseling content from sections 5.1, 5.2, and 17; many other statements are made without label support from the provided excerpts.
Suggested Improvement
Replace/augment the response with the label-supported suicidality content: (1) pooled analyses increased risk in ages 18–24 and close monitoring early/with dose changes (5.1), (2) smoking cessation-related neuropsychiatric adverse events including suicidal ideation/attempt/completed suicide and stop-contact guidance (5.2), and (3) patient/family day-to-day monitoring and reporting instructions (17).